Intensive glycemic control increases diabetes mortality, as seen in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The risk of …
Novo Nordisk said Thursday that Xultophy (ingredient: insulin degludec, liraglutide), its fixed ratio drug for treating type 2 diabetes, began receiving …